LA INMUNOTERAPIA EN EL MANEJO DEL CÁNCER RENAL METASTÁSICO: EN TRATAMIENTO CON INHIBIDORES DE CHECKPOINT PD-L1 Y/O ANTI-CTLA-4. A PROPÓSITO DE UN CASO: CASE REPORT ABOUT IMMUNOTHERAPY IN MANAGEMENT OF METASTATIC RENAL CANCER: TREATMENT WITH CHECKPOINT PD-L1 AND/OR ANTI-CTLA-4 INHIBITORS

Robert Malpartida-Palomino; Jesús Miguel  Malpartida Palomino; Joseph  Matos Malpartida

doi:10.25176/RFMH.v23i4.6202

Authors

Robert Malpartida-Palomino Servicio de Oncología Médica, Hospital Militar Central, Lima-Perú; IAFAS Ejercito del Perú
Jesús Miguel Malpartida - Palomino Servicio de Oftalmología Pediátrica Instituto Nacional de Salud del Niño de San Borja, Lima-Perú
Joseph Matos - Malpartida Universidad Peruana de Ciencias Aplicadas, Lima, Perú; Hospital Emergencia Ate -Vitarte

DOI:

https://doi.org/10.25176/RFMH.v23i4.6202

Keywords:

Kidney Cancer, Neoplasm Metastasis, Immunotherapy

Abstract

ABSTRACT

Approximately 15 percent of renal cell carcinoma (RCC) present as locally advanced or metastatic, where surgery is not curative. The prognosis of patients with advanced or metastatic CRC can vary from a few months to a few years, depending on the clinical, pathological, and radiological characteristics of the disease. The advent of the use of anti-monoclonal-based immunotherapy as checkpoint inhibitors in initial systemic therapy for advanced clear cell RCC. We will present a clinical case where immunotherapy plays a role through the use of anti-monoclonal drugs to treat a male patient with metastatic kidney disease who presents a clinical response after surgical treatment and immunotherapy for 2 years without evidence of oncological disease to date.

Downloads

Download data is not yet available.

Author Biographies

Robert Malpartida-Palomino, Servicio de Oncología Médica, Hospital Militar Central, Lima-Perú; IAFAS Ejercito del Perú

Oncólogo médico. Jefe Programa ONCOEP (Programa Oncológico del Ejercito del Perú)

Jesús Miguel Malpartida - Palomino, Servicio de Oftalmología Pediátrica Instituto Nacional de Salud del Niño de San Borja, Lima-Perú

Oftalmólogo. Jefe del Servicio de Oftalmología Pediátrica INSNSB

Joseph Matos - Malpartida, Universidad Peruana de Ciencias Aplicadas, Lima, Perú; Hospital Emergencia Ate -Vitarte

Estudiante de medicina

References

Kidney. Cancer Fact Sheets. Cancer Today. Globocan 2018. International Agency for Research on Cancer. World Health Organization (WHO). Available from: https://gco.iarc.fr/today/data/factsheets/cancers/29-Kidney-fact-sheet.pdf

Payet E, Pérez P, Poquioma E, et al. Registro de Cáncer de Lima Metropolitana. Incidencia y Mortalidad 2010 - 2012, Volumen 5. Lima 2016. Available from: http://www.inen.sld.pe/portal/documentos/pdf/banners_2014/2016/Registro%20de%20C%C3%A1ncer%20Lima%20Metropolitana%202010%20-%202012_02092016.pdf

Departamento de Epidemiología y Estadística del Cáncer - INEN. Datos Epidemiológicos. Casos nuevos de cáncer registrados en el INEN, periodo 2000 — 2017 (ambos sexos). Available from: https://portal.inen.sld.pe/indicadores-anuales-de-gestion-produccion-hospitalaria/

Sankin, A, Jacob C, Hongbei W, et al. Rate of Renal Cell Carcinoma Subtypes in Different Races.” International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2011; 37 (1): 29-32; discussion 33-34. Available from: https://pubmed.ncbi.nlm.nih.gov/21385477/

Cell cancer histological subtype distribution differs by race and sex. BJU International, 2016; 117 (2): 2860-65. Available from: https://pubmed.ncbi.nlm.nih.gov/25307281/

Howlader N, Noone AM, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2014, National Cancer Institute. 2019. Available from: https://seer.cancer.gov/archive/csr/1975_2014/index.html

Kiatte T, Patard J, Rakhee H, et al. Prognostic Impact of Tumor Size on pT2 Renal Cell Carcinoma: An International Multicenter Experience." The Journal of Urology, 2007, 178 (1): 35-40; discussion 40. Available from: https://www.auajournals.org/doi/10.1016/j.juro.2007.03.046

Lam 4, Klatte T, Patard J, et al. Prognostic Relevance of Tumour Size in T3a Renal Cell Carcinoma: A Multicentre Experience.” European Urology, 2007; 52 (1): 155-682. Available from: https://www.auajournals.org/doi/10.1016/j.juro.2007.03.046

Shao Y, Sanchao X, Guangxi S, et al. Prognostic Analysis of Postoperative Clinically Nonmetastatic Renal Cell Carcinoma. Cancer Medicine, December 2019. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6997064/

Dall’Oglio MF, Ribeiro-Filho LA, Antunes AA, et al. Microvascular Tumor Invasion, Tumor Size and Fuhrman Grade: A Pathological Triad for Prognostic Evaluation of Renal Cell Carcinoma.” The Journal of Urology, 2007;78 (2): 425-28; discussion 428. Available from: https://www.auajournals.org/doi/10.1016/j.juro.2007.03.128

Luciani LG, Cestari R, Tallarigo C. Incidental Renal Cell Carcinoma-Age and Stage Characterization and Clinical Implications: Study of 1092 Patients (1982-1997). Urology. 2000; 56 (1): 58-62. Available from: https://www.goldjournal.net/article/S0090-4295(00)00534-3/fulltext

Gary M, Bosniak M. How | Do it: Evaluating Renal Masses. Radiology 2005; 236 (2): 441—- S0. Available from: https://pubs.rsna.org/doi/full/10.1148/radiol.2362040218

NCCN Clinical Practice Guidelines in Oncology. Kidney Cancer. Version 1.2021 — July, 2020. Available from: https://www2.tri-kobe.org/nccn/guideline/urological/english/kidney.pdf

Escudier B, Porta C, Schmidinger M, Rioux-Leclercq N, Bex A, Khoo V, et al. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019;30(5):706-20. https://www.annalsofoncology.org/article/S0923-7534(19)31157-3/fulltext

Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2018;36(17):1714-68. https://www.ascopubs.org/doi/10.1200/JCO.2017.77.6385

Chen DS, Mellman I. Elements of cancer immunity and the cancer-immune set point. Nature. 2017;541(7637):321-30. https://pubmed.ncbi.nlm.nih.gov/28102259/

Rodríguez Martínez de Llano S, Jiménez-Vicioso A, Mahmood S, Carreras-Delgado JL. Clinical impact of 18F-FDG PET in management of patients with renal cell carcinoma. Rev Esp Med Nucl. 1 de enero de 2010;29(1):12-9. https://doi.org/10.1016/j.remn.2009.11.008